CN1686496A - Medicine for treating neurasthenia and its preparation method - Google Patents

Medicine for treating neurasthenia and its preparation method Download PDF

Info

Publication number
CN1686496A
CN1686496A CN 200510009888 CN200510009888A CN1686496A CN 1686496 A CN1686496 A CN 1686496A CN 200510009888 CN200510009888 CN 200510009888 CN 200510009888 A CN200510009888 A CN 200510009888A CN 1686496 A CN1686496 A CN 1686496A
Authority
CN
China
Prior art keywords
radix
rhizoma
fructus
group
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510009888
Other languages
Chinese (zh)
Other versions
CN1298383C (en
Inventor
蒋希民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2005100098886A priority Critical patent/CN1298383C/en
Publication of CN1686496A publication Critical patent/CN1686496A/en
Application granted granted Critical
Publication of CN1298383C publication Critical patent/CN1298383C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

A Chinese medicine in the form of pill for treating neurasthenia is prepared from the components A and B through pulverizing component A, extracting from component B, proportional mixing and pilling. Said component A is composed of 5 Chinese-medicinal materials including American ginseng, pilose antler, etc. Said component B is composed of 17 Chinese-medicinal materials including white peony root, coix seed, liquorice root, etc.

Description

A kind of medicine for the treatment of neurasthenia and preparation method thereof
Technical field:
The present invention relates to a kind of compositions of the neurasthenia's of treatment medicine and manufacture method is provided.
Background technology:
The neurasthenia is clinical common and disease that heal than refractory, and sickness rate is the trend that rises year by year, does not more form obstinate asomnia for a long time.This disease of neurasthenia in motherland's medical science, belong to be insomnia, strongly fragrant disease, Bulbus Lilii syndrome, climacteric syndrome category.The cause of disease is owing to happiness, anger, melancholy, think of, compassion, fears, shies damaged by excess of seven emotions, is the neurasthenia and cause function of five internal organs imbalance initiation, and the neurasthenia deficient syndrome is more than the case of a physically strong patient running a high fever.The existing following problem of medicine (comprising Chinese medicine, Western medicine) ubiquity that is used for the treatment of neurasthenia: one, the therapeutical effect of some medicine is imprecise, and patient takes medicine by package insert or doctor's advice and often can not take effect.Though two, some medicine instant effect, it is not lasting to act on, and must adhere to for a long time taking medicine, and patient is felt exhausted curative effect is descended.Though three, some medicine is effective in cure, can not cure, in case drug withdrawal is promptly fallen ill, make patient produce dependency easily.Four, some poison of drug side effect is bigger, takes for a long time the healthy of patient done harm rather than good.
Summary of the invention:
The objective of the invention is that the therapeutical effect that exists for the medicine that solves existing treatment neurasthenia is imprecise, effect is lasting, toxic and side effects is big, be easy to generate dependent problem, a kind of medicine for the treatment of neurasthenia and preparation method thereof is provided, and medicine of the present invention has that therapeutical effect is definite, cure rate is high, no dependence, the characteristics that have no side effect.Method of the present invention has the high characteristics of effective ingredient extraction ratio.Medicine of the present invention is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 4~10, Radix Polygalae: 2~9, the Radix Aucklandiae: 2~9, Cornu Cervi Pantotrichum: 2~9, Concha Margaritifera: 4~10, Dens Draconis: 4~10, Concha Ostreae: 3~10, Semen Ziziphi Spinosae (parched): 4~10, succinum: 3~9, Magnetitum: 3~9, Massa Medicata Fermentata: 2~8, Fructus Citri Sarcodactylis: 2~8, Poria cum Radix Pini: 3~10, Ganoderma: 4~10, Radix Curcumae: 3~10, Moschus: 1~8; The B group is: Radix Bupleuri: 3~10, the Radix Paeoniae Alba: 3~10, Rhizoma Pinelliae Preparatum: 3~10, Semen Coicis: 3~10, Fructus Schisandrae Chinensis: 3~10, Caulis Polygoni Multiflori: 3~10, Bulbus Lilii: 3~10, the Radix Rehmanniae: 3~10, Rhizoma Gastrodiae: 3~10, Ramulus Uncariae Cum Uncis: 3~10, Medulla Junci: 2~9, Caulis Bambusae In Taenia: 2~9, Spica Prunellae: 2~9, Flos Chrysanthemi: 2~9, Fructus Tritici Levis: 3~10, Fructus Jujubae: 2~9, Radix Glycyrrhizae: 2~9, Folium Pini: 2~9, Rhizoma Acori Graminei: 3~10, Folium Kaki: 2~9, Rhizoma et radix valerianae: 3~10, Flos Albiziae: 2~9, Fructus Gardeniae: 2~9, Radix Angelicae Sinensis: 2~9, the Radix Astragali: 3~10, Carapax et Plastrum Testudinis: 2~9, Rhizoma Dioscoreae: 2~9, Radix Ophiopogonis: 3~10.Manufacture method of the present invention is: it is standby that the raw material powder of A group is broken into 100~150 purpose fine powders, the raw material water of B group is decocted twice, merge decoction liquor twice, being concentrated into relative density is the clear paste of 1.2~1.3 (60~65 ℃), the clear paste mixing and stirring of material powder that A is organized and B group raw material is made the watered pill and is got final product then.The present invention is divided into A group and B group with the raw material of medicine, according to the processing technology difference it is separated.Clinical practice proves that the medicine material of B group must can propose its effective ingredient through water extraction, reaches good curative effect.
For showing the curative effect of medicine of the present invention, see also following clinical data to the treatment neurasthenia:
One, physical data: select 87 routine neurasthenia patients at random, male patient 42 people wherein, minimum 17 years old of age, maximum 70 years old, average 37.3 years old; Female patient 45 people, minimum 18 years old, maximum 68 years old, average 34.1 years old.The course of disease is the shortest 6 months, and is the longest 2.5 years.
Two, diagnostic criteria: 1, patient's brain is easily tired, poor memory.2, easily worried, be nervous and can not relax, LA or depression are arranged.3, spirit is easily excited, shows as to recall and association increases and loses control of, and excitement can have unplessantness displeasure.4, with tension headache.5, sleep disorder, as difficulty falling asleep, by dream hardship, the easy early awakening that is difficult to sleep soundly still feels tired after waking up.6,, not normal as the rhythm of the heart, blood pressure is higher or on the low side, hyperhidrosis, acra are felt cold, anorexia, constipation or diarrhoea, menoxenia, seminal emission, premature ejaculation or sexual impotence with autonomic nervous dysfunction.
Three, administrated method: take medicine for early, middle and late three times, take medicine of the present invention (watered pill) 10g morning, respectively obey 20g before noon, the supper, after sb.'s illness took a favorable turn, early, middle and lately respectively obey 10g, note having a rest on time, avoid feelings will to stimulate, 30 days is a course of treatment.
Four, criterion of therapeutical effect: 1, the one night sleep was recovery from illness in 7~8 hours.Slept 6 hours, but few dream in the sleep, can reach the deep sleep, the back of waking up is energetic also to be recovery from illness; 2, sleep 5 hours and few dream are produce effects; 3, sleep was effective in 4 hours; 4, sleep be invalid in 2~3 hours, but was effective for the person of lying awake all night before treating.
Five, efficacy analysis: 87 routine patients person 55 people that wherein do not lie awake all night through a course of therapy 21 people that fully recover, account for 38.18%; Produce effects 12 people account for 21.82%; Effective 22 people account for 40%; Through two course of therapy, 27 people that fully recover, account for 49.09%; Produce effects 5 people account for 9.09%; Effective 2 people account for 3.64%.Surplus 32 people all for sleeping at 2~4 hours, and through a course of therapy, 23 people that fully recover account for 71.88%; Produce effects 4 people account for 12.5%; Effective 5 people account for 15.62%.Through two course of therapy, 7 people that fully recover account for 21.88%; Produce effects 2 people account for 6.25%.Recovery from illness 78 people in 87 routine patients, cure rate is 89.66%; Produce effects 7 people account for 8.05%; Effective 2 people account for 2.03%, and total effective rate is 100%.All cases all promptly began to take effect after medication in 3~5 days.
Medicine of the present invention has regulating the flow of QI to alleviate depression, brain-care, tranquilizing by nourishing the heart, nourishing and fit keeping function, enhancing immunity, defying age, and the effect of YANG hyperactivity suppressing blood pressure lowering is arranged.But it is useful and do not have overslaugh to hypotension and normal arterial pressure.The present invention has that the effect of treatment neurasthenia is definite, cure rate is high, no dependence, the advantage that has no side effect.
The specific embodiment:
The specific embodiment one: present embodiment is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 4~10, Radix Polygalae: 2~9, the Radix Aucklandiae: 2~9, Cornu Cervi Pantotrichum: 2~9, Concha Margaritifera: 4~10, Dens Draconis: 4~10, Concha Ostreae: 3~10, Semen Ziziphi Spinosae (parched): 4~10, succinum: 3~9, Magnetitum: 3~9, Massa Medicata Fermentata: 2~8, Fructus Citri Sarcodactylis: 2~8, Poria cum Radix Pini: 3~10, Ganoderma: 4~10, Radix Curcumae: 3~10, Moschus: 1~8; The B group is: Radix Bupleuri: 3~10, the Radix Paeoniae Alba: 3~10, Rhizoma Pinelliae Preparatum: 3~10, Semen Coicis: 3~10, Fructus Schisandrae Chinensis: 3~10, Caulis Polygoni Multiflori: 3~10, Bulbus Lilii: 3~10, the Radix Rehmanniae: 3~10, Rhizoma Gastrodiae: 3~10, Ramulus Uncariae Cum Uncis: 3~10, Medulla Junci: 2~9, Caulis Bambusae In Taenia: 2~9, Spica Prunellae: 2~9, Flos Chrysanthemi: 2~9, Fructus Tritici Levis: 3~10, Fructus Jujubae: 2~9, Radix Glycyrrhizae: 2~9, Folium Pini: 2~9, Rhizoma Acori Graminei: 3~10, Folium Kaki: 2~9, Rhizoma et radix valerianae: 3~10, Flos Albiziae: 2~9, Fructus Gardeniae: 2~9, Radix Angelicae Sinensis: 2~9, the Radix Astragali: 3~10, Carapax et Plastrum Testudinis: 2~9, Rhizoma Dioscoreae: 2~9, Radix Ophiopogonis: 3~10.The manufacture method of present embodiment is: it is standby that the raw material powder of A group is broken into 100~150 purpose fine powders, the raw material water of B group is decocted twice, merge decoction liquor twice, being concentrated into relative density is the clear paste of 1.2~1.3 (60~65 ℃), the clear paste mixing and stirring of material powder that A is organized and B group raw material is made the watered pill and is got final product then.
The specific embodiment two: present embodiment is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 4.5~9.5, Radix Polygalae: 2.5~8.5, the Radix Aucklandiae: 2.5~8.5, Cornu Cervi Pantotrichum: 2.5~8.5, Concha Margaritifera: 4.5~9.5, Dens Draconis: 4.5~9.5, Concha Ostreae: 3.5~9.5, Semen Ziziphi Spinosae (parched): 4.5~9.5, succinum: 3.5~8.5, Magnetitum: 3.5~8.5, Massa Medicata Fermentata: 2.5~7.5, Fructus Citri Sarcodactylis: 2.5~7.5, Poria cum Radix Pini: 3.5~9.5, Ganoderma: 4.5~9.5, Radix Curcumae: 3.5~9.5, Moschus: 1.5~7.5; The B group is: Radix Bupleuri: 3.5~9.5, the Radix Paeoniae Alba: 3.5~9.5, Rhizoma Pinelliae Preparatum: 3.5~9.5, Semen Coicis: 3.5~9.5, Fructus Schisandrae Chinensis: 3.5~9.5, Caulis Polygoni Multiflori: 3.5~9.5, Bulbus Lilii: 3.5~9.5, the Radix Rehmanniae: 3.5~9.5, Rhizoma Gastrodiae: 3.5~9.5, Ramulus Uncariae Cum Uncis: 3.5~9.5, Medulla Junci: 2.5~8.5, Caulis Bambusae In Taenia: 2.5~8.5, Spica Prunellae: 2.5~8.5, Flos Chrysanthemi: 2.5~8.5, Fructus Tritici Levis: 3.5~9.5, Fructus Jujubae: 2.5~8.5, Radix Glycyrrhizae: 2.5~8.5, Folium Pini: 2.5~8.5, Rhizoma Acori Graminei: 3.5~9.5, Folium Kaki: 2.5~8.5, Rhizoma et radix valerianae: 3.5~9.5, Flos Albiziae: 2.5~8.5, Fructus Gardeniae: 2.5~8.5, Radix Angelicae Sinensis: 2.5~8.5, the Radix Astragali: 3.5~9.5, Carapax et Plastrum Testudinis: 2.5~8.5, Rhizoma Dioscoreae: 2.5~8.5, Radix Ophiopogonis: 3.5~9.5.Other method is identical with the specific embodiment one.
The specific embodiment three: present embodiment is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 4.9~9.1, Radix Polygalae: 2.9~8.1, the Radix Aucklandiae: 2.9~8.1, Cornu Cervi Pantotrichum: 2.9~8.1, Concha Margaritifera: 4.9~9.1, Dens Draconis: 4.9~9.1, Concha Ostreae: 3.9~9.1, Semen Ziziphi Spinosae (parched): 4.9~9.1, succinum: 3.9~8.1, Magnetitum: 3.9~8.1, Massa Medicata Fermentata: 2.9~7.1, Fructus Citri Sarcodactylis: 2.9~7.1, Poria cum Radix Pini: 3.9~9.1, Ganoderma: 4.9~9.1, Radix Curcumae: 3.9~9.1, Moschus: 1.9~7.1; The B group is: Radix Bupleuri: 3.9~9.1, the Radix Paeoniae Alba: 3.9~9.1, Rhizoma Pinelliae Preparatum: 3.9~9.1, Semen Coicis: 3.9~9.1, Fructus Schisandrae Chinensis: 3.9~9.1, Caulis Polygoni Multiflori: 3.9~9.1, Bulbus Lilii: 3.9~9.1, the Radix Rehmanniae: 3.9~9.1, Rhizoma Gastrodiae: 3.9~9.1, Ramulus Uncariae Cum Uncis: 3.9~9.1, Medulla Junci: 2.9~8.1, Caulis Bambusae In Taenia: 2.9~8.1, Spica Prunellae: 2.9~8.1, Flos Chrysanthemi: 2.9~8.1, Fructus Tritici Levis: 3.9~9.1, Fructus Jujubae: 2.9~8.1, Radix Glycyrrhizae: 2.9~8.1, Folium Pini: 2.9~8.1, Rhizoma Acori Graminei: 3.9~9.1, Folium Kaki: 2.9~8.1, Rhizoma et radix valerianae: 3.9~9.1, Flos Albiziae: 2.9~8.1, Fructus Gardeniae: 2.9~8.1, Radix Angelicae Sinensis: 2.9~8.1, the Radix Astragali: 3.9~9.1, Carapax et Plastrum Testudinis: 2.9~8.1, Rhizoma Dioscoreae: 2.9~8.1, Radix Ophiopogonis: 3.9~9.1.Other method is identical with the specific embodiment one.
The specific embodiment four: present embodiment is made by following raw materials by weight portion, and wherein the A group is: Radix Panacis Quinquefolii: 5, Radix Polygalae: 4, the Radix Aucklandiae: 4, Cornu Cervi Pantotrichum: 4, Concha Margaritifera: 5, Dens Draconis: 5, Concha Ostreae: 5, Semen Ziziphi Spinosae (parched): 5, succinum: 5, Magnetitum: 5, Massa Medicata Fermentata: 4, Fructus Citri Sarcodactylis: 4, Poria cum Radix Pini: 5, Ganoderma: 5, Radix Curcumae: 5, Moschus: 3; The B group is: Radix Bupleuri: 5, the Radix Paeoniae Alba: 5, Rhizoma Pinelliae Preparatum: 5, Semen Coicis: 5, Fructus Schisandrae Chinensis: 5, Caulis Polygoni Multiflori: 5, Bulbus Lilii: 5, the Radix Rehmanniae: 5, Rhizoma Gastrodiae: 5, Ramulus Uncariae Cum Uncis: 5, Medulla Junci: 4, Caulis Bambusae In Taenia: 4, Spica Prunellae: 4, Flos Chrysanthemi: 4, Fructus Tritici Levis: 5, Fructus Jujubae: 4, Radix Glycyrrhizae: 4, Folium Pini: 4, Rhizoma Acori Graminei: 5, Folium Kaki: 4, Rhizoma et radix valerianae: 5, Flos Albiziae: 4, Fructus Gardeniae: 4, Radix Angelicae Sinensis: 4, the Radix Astragali: 5, Carapax et Plastrum Testudinis: 4, Rhizoma Dioscoreae: 4, Radix Ophiopogonis: 5.Other method is identical with the specific embodiment one.

Claims (5)

1, a kind of medicine for the treatment of neurasthenia, it is characterized in that it is made by following raw materials by weight portion, wherein the A group is: Radix Panacis Quinquefolii: 4~10, Radix Polygalae: 2~9, the Radix Aucklandiae: 2~9, Cornu Cervi Pantotrichum: 2~9, Concha Margaritifera: 4~10, Dens Draconis: 4~10, Concha Ostreae: 3~10, Semen Ziziphi Spinosae (parched): 4~10, succinum: 3~9, Magnetitum: 3~9, Massa Medicata Fermentata: 2~8, Fructus Citri Sarcodactylis: 2~8, Poria cum Radix Pini: 3~10, Ganoderma: 4~10, Radix Curcumae: 3~10, Moschus: 1~8; The B group is: Radix Bupleuri: 3~10, the Radix Paeoniae Alba: 3~10, Rhizoma Pinelliae Preparatum: 3~10, Semen Coicis: 3~10, Fructus Schisandrae Chinensis: 3~10, Caulis Polygoni Multiflori: 3~10, Bulbus Lilii: 3~10, the Radix Rehmanniae: 3~10, Rhizoma Gastrodiae: 3~10, Ramulus Uncariae Cum Uncis: 3~10, Medulla Junci: 2~9, Caulis Bambusae In Taenia: 2~9, Spica Prunellae: 2~9, Flos Chrysanthemi: 2~9, Fructus Tritici Levis: 3~10, Fructus Jujubae: 2~9, Radix Glycyrrhizae: 2~9, Folium Pini: 2~9, Rhizoma Acori Graminei: 3~10, Folium Kaki: 2~9, Rhizoma et radix valerianae: 3~10, Flos Albiziae: 2~9, Fructus Gardeniae: 2~9, Radix Angelicae Sinensis: 2~9, the Radix Astragali: 3~10, Carapax et Plastrum Testudinis: 2~9, Rhizoma Dioscoreae: 2~9, Radix Ophiopogonis: 3~10.
2, a kind of medicine for the treatment of neurasthenia according to claim 1, it is characterized in that it is made by following raw materials by weight portion, wherein the A group is: Radix Panacis Quinquefolii: 4.5~9.5, Radix Polygalae: 2.5~8.5, the Radix Aucklandiae: 2.5~8.5, Cornu Cervi Pantotrichum: 2.5~8.5, Concha Margaritifera: 4.5~9.5, Dens Draconis: 4.5~9.5, Concha Ostreae: 3.5~9.5, Semen Ziziphi Spinosae (parched): 4.5~9.5, succinum: 3.5~8.5, Magnetitum: 3.5~8.5, Massa Medicata Fermentata: 2.5~7.5, Fructus Citri Sarcodactylis: 2.5~7.5, Poria cum Radix Pini: 3.5~9.5, Ganoderma: 4.5~9.5, Radix Curcumae: 3.5~9.5, Moschus: 1.5~7.5; The B group is: Radix Bupleuri: 3.5~9.5, the Radix Paeoniae Alba: 3.5~9.5, Rhizoma Pinelliae Preparatum: 3.5~9.5, Semen Coicis: 3.5~9.5, Fructus Schisandrae Chinensis: 3.5~9.5, Caulis Polygoni Multiflori: 3.5~9.5, Bulbus Lilii: 3.5~9.5, the Radix Rehmanniae: 3.5~9.5, Rhizoma Gastrodiae: 3.5~9.5, Ramulus Uncariae Cum Uncis: 3.5~9.5, Medulla Junci: 2.5~8.5, Caulis Bambusae In Taenia: 2.5~8.5, Spica Prunellae: 2.5~8.5, Flos Chrysanthemi: 2.5~8.5, Fructus Tritici Levis: 3.5~9.5, Fructus Jujubae: 2.5~8.5, Radix Glycyrrhizae: 2.5~8.5, Folium Pini: 2.5~8.5, Rhizoma Acori Graminei: 3.5~9.5, Folium Kaki: 2.5~8.5, Rhizoma et radix valerianae: 3.5~9.5, Flos Albiziae: 2.5~8.5, Fructus Gardeniae: 2.5~8.5, Radix Angelicae Sinensis: 2.5~8.5, the Radix Astragali: 3.5~9.5, Carapax et Plastrum Testudinis: 2.5~8.5, Rhizoma Dioscoreae: 2.5~8.5, Radix Ophiopogonis: 3.5~9.5.
3, a kind of medicine for the treatment of neurasthenia according to claim 1, it is characterized in that it is made by following raw materials by weight portion, wherein the A group is: Radix Panacis Quinquefolii: 4.9~9.1, Radix Polygalae: 2.9~8.1, the Radix Aucklandiae: 2.9~8.1, Cornu Cervi Pantotrichum: 2.9~8.1, Concha Margaritifera: 4.9~9.1, Dens Draconis: 4.9~9.1, Concha Ostreae: 3.9~9.1, Semen Ziziphi Spinosae (parched): 4.9~9.1, succinum: 3.9~8.1, Magnetitum: 3.9~8.1, Massa Medicata Fermentata: 2.9~7.1, Fructus Citri Sarcodactylis: 2.9~7.1, Poria cum Radix Pini: 3.9~9.1, Ganoderma: 4.9~9.1, Radix Curcumae: 3.9~9.1, Moschus: 1.9~7.1; The B group is: Radix Bupleuri: 3.9~9.1, the Radix Paeoniae Alba: 3.9~9.1, Rhizoma Pinelliae Preparatum: 3.9~9.1, Semen Coicis: 3.9~9.1, Fructus Schisandrae Chinensis: 3.9~9.1, Caulis Polygoni Multiflori: 3.9~9.1, Bulbus Lilii: 3.9~9.1, the Radix Rehmanniae: 3.9~9.1, Rhizoma Gastrodiae: 3.9~9.1, Ramulus Uncariae Cum Uncis: 3.9~9.1, Medulla Junci: 2.9~8.1, Caulis Bambusae In Taenia: 2.9~8.1, Spica Prunellae: 2.9~8.1, Flos Chrysanthemi: 2.9~8.1, Fructus Tritici Levis: 3.9~9.1, Fructus Jujubae: 2.9~8.1, Radix Glycyrrhizae: 2.9~8.1, Folium Pini: 2.9~8.1, Rhizoma Acori Graminei: 3.9~9.1, Folium Kaki: 2.9~8.1, Rhizoma et radix valerianae: 3.9~9.1, Flos Albiziae: 2.9~8.1, Fructus Gardeniae: 2.9~8.1, Radix Angelicae Sinensis: 2.9~8.1, the Radix Astragali: 3.9~9.1, Carapax et Plastrum Testudinis: 2.9~8.1, Rhizoma Dioscoreae: 2.9~8.1, Radix Ophiopogonis: 3.9~9.1.
4, a kind of medicine for the treatment of neurasthenia according to claim 1, it is characterized in that it is made by following raw materials by weight portion, wherein the A group is: Radix Panacis Quinquefolii: 5, Radix Polygalae: 4, the Radix Aucklandiae: 4, Cornu Cervi Pantotrichum: 4, Concha Margaritifera: 5, Dens Draconis: 5, Concha Ostreae: 5, Semen Ziziphi Spinosae (parched): 5, succinum: 5, Magnetitum: 5, Massa Medicata Fermentata: 4, Fructus Citri Sarcodactylis: 4, Poria cum Radix Pini: 5, Ganoderma: 5, Radix Curcumae: 5, Moschus: 3; The B group is: Radix Bupleuri: 5, the Radix Paeoniae Alba: 5, Rhizoma Pinelliae Preparatum: 5, Semen Coicis: 5, Fructus Schisandrae Chinensis: 5, Caulis Polygoni Multiflori: 5, Bulbus Lilii: 5, the Radix Rehmanniae: 5, Rhizoma Gastrodiae: 5, Ramulus Uncariae Cum Uncis: 5, Medulla Junci: 4, Caulis Bambusae In Taenia: 4, Spica Prunellae: 4, Flos Chrysanthemi: 4, Fructus Tritici Levis: 5, Fructus Jujubae: 4, Radix Glycyrrhizae: 4, Folium Pini: 4, Rhizoma Acori Graminei: 5, Folium Kaki: 4, Rhizoma et radix valerianae: 5, Flos Albiziae: 4, Fructus Gardeniae: 4, Radix Angelicae Sinensis: 4, the Radix Astragali: 5, Carapax et Plastrum Testudinis: 4, Rhizoma Dioscoreae: 4, Radix Ophiopogonis: 5.
5, a kind of manufacture method for the treatment of the neurasthenia medicine, it is standby to it is characterized in that the raw material powder that described A organizes is broken into 100~150 purpose fine powders, the raw material water of B group is decocted twice, merge decoction liquor twice, be concentrated into relative density and be 1.2~1.3 clear paste, the clear paste mixing and stirring of material powder that A is organized and B group raw material is made the watered pill and is got final product then.
CNB2005100098886A 2005-04-13 2005-04-13 Medicine for treating neurasthenia and its preparation method Expired - Fee Related CN1298383C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100098886A CN1298383C (en) 2005-04-13 2005-04-13 Medicine for treating neurasthenia and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100098886A CN1298383C (en) 2005-04-13 2005-04-13 Medicine for treating neurasthenia and its preparation method

Publications (2)

Publication Number Publication Date
CN1686496A true CN1686496A (en) 2005-10-26
CN1298383C CN1298383C (en) 2007-02-07

Family

ID=35304538

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100098886A Expired - Fee Related CN1298383C (en) 2005-04-13 2005-04-13 Medicine for treating neurasthenia and its preparation method

Country Status (1)

Country Link
CN (1) CN1298383C (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100394951C (en) * 2006-01-26 2008-06-18 王信锁 Medicine for treating insomnia and preparation method thereof
CN101703622A (en) * 2009-09-17 2010-05-12 杭州六易科技有限公司 Preparation method of buccal tablet for improving sleeping
CN1994451B (en) * 2006-12-27 2010-06-02 河南太龙药业股份有限公司 Chinese medicinal composition for treating depression, its preparation method and application
CN101912434A (en) * 2010-07-30 2010-12-15 郑家桂 Medicament for treating hypertension and insomnia and preparation method thereof
CN101947263A (en) * 2010-09-01 2011-01-19 刘思波 Medicament for treating neurasthenia and insomnia
CN101062330B (en) * 2006-04-26 2011-01-19 成都地奥九泓制药厂 Chinese medicine composition for improving sleeping and preparing method thereof
CN101229247B (en) * 2007-12-28 2011-06-01 重庆理工大学 Medicine preparation for treating insomnia and preparing method thereof
CN102178777A (en) * 2011-04-15 2011-09-14 刘晓艳 Chinese patent drug for treating nervous breakdown
CN102225164A (en) * 2011-05-20 2011-10-26 滕淑玲 Bag for treating amnesia and calming nerves and preparation method thereof
CN102258742A (en) * 2010-05-27 2011-11-30 倪健 Chinese medicinal medicine composition for treating depression and preparation method thereof
CN102512633A (en) * 2011-12-23 2012-06-27 荣成市崖头美全口腔诊所 Traditional Chinese medicinal composition for treating insomnia
CN102552671A (en) * 2012-01-12 2012-07-11 李玉梅 Medicament for curing neurasthenia
CN102698094A (en) * 2012-06-18 2012-10-03 田冬梅 Medicament for treating female depression
CN102784308A (en) * 2012-07-24 2012-11-21 马千里 Chinese medicine composition for treating neurasthenia
CN102861295A (en) * 2012-09-17 2013-01-09 袁兵 Traditional Chinese medicine preparation for treating neurasthenia
CN103656519A (en) * 2013-12-16 2014-03-26 青岛百瑞吉生物工程有限公司 Traditional Chinese medicine preparation for curing neurasthenia as well as preparation method and application thereof
CN103961578A (en) * 2014-05-15 2014-08-06 吴春来 Traditional Chinese medicine medicinal liquor for treating neurasthenia
CN104306525A (en) * 2014-10-23 2015-01-28 张益玲 Traditional Chinese medicine preparation for treating neurasthenia
CN105031481A (en) * 2015-09-18 2015-11-11 全椒先奇医药科技有限公司 Pharmaceutic preparation for treating neurasthenia
CN105148189A (en) * 2015-09-09 2015-12-16 孔令刚 Traditional Chinese medicine preparation for curing insomnia
CN105267729A (en) * 2015-02-12 2016-01-27 济南舜景医药科技有限公司 Traditional Chinese medicine for treating insomnia
CN105747721A (en) * 2016-02-28 2016-07-13 宁波高新区苗姑养生科技有限公司 Health care pillow for preventing and treating childhood phobia
CN105902569A (en) * 2016-05-26 2016-08-31 吉林省中韩动物科学研究院 Composition for improving sleep disorder as well as preparation method and application thereof
CN106930101A (en) * 2017-02-26 2017-07-07 浙江峰赫纺织有限公司 A kind of pillow-cover towel fabric of relieving mental strain and helping sleep

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142910B (en) * 2013-03-08 2014-07-09 张风华 Spirit-quieting navel paste

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1085788A (en) * 1993-06-26 1994-04-27 长春市白山药物开发研究所 Oral liquid

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100394951C (en) * 2006-01-26 2008-06-18 王信锁 Medicine for treating insomnia and preparation method thereof
CN101062330B (en) * 2006-04-26 2011-01-19 成都地奥九泓制药厂 Chinese medicine composition for improving sleeping and preparing method thereof
CN1994451B (en) * 2006-12-27 2010-06-02 河南太龙药业股份有限公司 Chinese medicinal composition for treating depression, its preparation method and application
CN101229247B (en) * 2007-12-28 2011-06-01 重庆理工大学 Medicine preparation for treating insomnia and preparing method thereof
CN101703622A (en) * 2009-09-17 2010-05-12 杭州六易科技有限公司 Preparation method of buccal tablet for improving sleeping
CN101703622B (en) * 2009-09-17 2013-04-17 杭州六易科技有限公司 Preparation method of buccal tablet for improving sleeping
CN102258742A (en) * 2010-05-27 2011-11-30 倪健 Chinese medicinal medicine composition for treating depression and preparation method thereof
CN101912434A (en) * 2010-07-30 2010-12-15 郑家桂 Medicament for treating hypertension and insomnia and preparation method thereof
CN101947263A (en) * 2010-09-01 2011-01-19 刘思波 Medicament for treating neurasthenia and insomnia
CN101947263B (en) * 2010-09-01 2011-09-07 刘思波 Medicament for treating neurasthenia and insomnia
CN102178777A (en) * 2011-04-15 2011-09-14 刘晓艳 Chinese patent drug for treating nervous breakdown
CN102225164B (en) * 2011-05-20 2012-11-14 滕淑玲 Bag for treating amnesia and calming nerves and preparation method thereof
CN102225164A (en) * 2011-05-20 2011-10-26 滕淑玲 Bag for treating amnesia and calming nerves and preparation method thereof
CN102512633A (en) * 2011-12-23 2012-06-27 荣成市崖头美全口腔诊所 Traditional Chinese medicinal composition for treating insomnia
CN102512633B (en) * 2011-12-23 2014-03-12 赵丽华 Traditional Chinese medicinal composition for treating insomnia
CN102552671A (en) * 2012-01-12 2012-07-11 李玉梅 Medicament for curing neurasthenia
CN102552671B (en) * 2012-01-12 2013-08-28 李玉梅 Medicament for curing neurasthenia
CN102698094A (en) * 2012-06-18 2012-10-03 田冬梅 Medicament for treating female depression
CN102784308A (en) * 2012-07-24 2012-11-21 马千里 Chinese medicine composition for treating neurasthenia
CN102861295A (en) * 2012-09-17 2013-01-09 袁兵 Traditional Chinese medicine preparation for treating neurasthenia
CN102861295B (en) * 2012-09-17 2014-10-22 袁兵 Traditional Chinese medicine preparation for treating neurasthenia
CN103656519A (en) * 2013-12-16 2014-03-26 青岛百瑞吉生物工程有限公司 Traditional Chinese medicine preparation for curing neurasthenia as well as preparation method and application thereof
CN103961578A (en) * 2014-05-15 2014-08-06 吴春来 Traditional Chinese medicine medicinal liquor for treating neurasthenia
CN104306525A (en) * 2014-10-23 2015-01-28 张益玲 Traditional Chinese medicine preparation for treating neurasthenia
CN105267729A (en) * 2015-02-12 2016-01-27 济南舜景医药科技有限公司 Traditional Chinese medicine for treating insomnia
CN105148189A (en) * 2015-09-09 2015-12-16 孔令刚 Traditional Chinese medicine preparation for curing insomnia
CN105031481A (en) * 2015-09-18 2015-11-11 全椒先奇医药科技有限公司 Pharmaceutic preparation for treating neurasthenia
CN105747721A (en) * 2016-02-28 2016-07-13 宁波高新区苗姑养生科技有限公司 Health care pillow for preventing and treating childhood phobia
CN105902569A (en) * 2016-05-26 2016-08-31 吉林省中韩动物科学研究院 Composition for improving sleep disorder as well as preparation method and application thereof
CN105902569B (en) * 2016-05-26 2019-07-09 吉林省中韩动物科学研究院 Improve the composition and its preparation method and application of sleep disturbance
CN106930101A (en) * 2017-02-26 2017-07-07 浙江峰赫纺织有限公司 A kind of pillow-cover towel fabric of relieving mental strain and helping sleep
CN106930101B (en) * 2017-02-26 2019-07-30 浙江峰赫纺织有限公司 A kind of pillow-cover towel fabric of relieving mental strain and helping sleep

Also Published As

Publication number Publication date
CN1298383C (en) 2007-02-07

Similar Documents

Publication Publication Date Title
CN1298383C (en) Medicine for treating neurasthenia and its preparation method
CN101670076B (en) Traditional Chinese medicine composition for treating disease of chronic nephritis and preparation method thereof
CN101711850B (en) Traditional Chinese medicine composition for treating symptoms of myocardial ischemia, palpitation and severe palpitation and preparation method
CN102233112B (en) Pharmaceutical composition for treatment of lumbar disc herniation and preparation method thereof
CN101485830A (en) Pure Chinese medicine anti-aging health-care capsule
CN102988750A (en) TCM (Traditional Chinese medicine) composition for treating diabetes and preparation method thereof
CN103127472B (en) Traditional Chinese medicine compound for refractory insomnia
CN101485820B (en) Health-care bolus for persons in middle and old age
CN108355088A (en) A kind of spina date seed medicinal liquor and preparation method thereof improving sleep quality
CN1352983A (en) Chinese medicine for treating hypertension
CN101549078A (en) Pharmaceutical composition for treating intractable insomnia and preparation method thereof
CN105796845A (en) Application of medicine composition in preparing medicine for treating female climacteric syndromes
CN115779064A (en) Astragalus root strengthening body resistance and preparation and application thereof
CN105535127A (en) Foot bath powder containing folium artemisiae argyi dregs and achieving sleep improvement function and preparation method thereof
CN104938727A (en) Preparation method of insomnia resistance substitutional tea
CN104524479B (en) A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof
CN101675983A (en) Warming and tonifying agent for qi-deficiency syndrome
CN104225425A (en) Chinese herbal preparation for enhancing immunity, improving sleep and preventing cardio-cerebrovascular disease, and preparation method thereof
CN104127663A (en) Chinese patent medicine used for treating yin-deficiency-caused-fire-excess type insomnia during menstruation
CN105963505A (en) Traditional Chinese medicinal foot bath powder capable of treating insomnia
CN101391001A (en) Traditional Chinese medicine composition for preventing altitude stress and preparation method thereof
CN104920742A (en) Anti-insomnia substitutional tea
CN104043084A (en) Cell beauty preparation
CN105396028A (en) Traditional Chinese medicine heath care tea for soothing nerves and nourishing brain
CN105412823A (en) Pharmaceutical preparation for treating male climacteric syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070207